Triple-action diabetes jab shown to reduce blood sugar and body weight

Triple-action diabetes jab shown to reduce blood sugar and body weight The Guardian Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits Reuters ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes Fierce Biotech Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications investor.lilly.com A new wave of weight-loss therapies aims to be better than today’s GLP-1s MarketWatch